Campbell & CO Investment Adviser LLC Takes Position in Organon & Co. $OGN

Campbell & CO Investment Adviser LLC acquired a new stake in Organon & Co. (NYSE:OGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 77,191 shares of the company’s stock, valued at approximately $747,000.

Other large investors have also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management bought a new position in shares of Organon & Co. in the second quarter valued at approximately $26,000. Hantz Financial Services Inc. grew its stake in Organon & Co. by 293.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after buying an additional 1,995 shares during the last quarter. Ransom Advisory Ltd bought a new position in Organon & Co. in the 1st quarter worth $32,000. SouthState Corp lifted its position in Organon & Co. by 1,857.0% during the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock worth $38,000 after acquiring an additional 3,714 shares during the last quarter. Finally, Brooklyn Investment Group boosted its holdings in Organon & Co. by 1,012.3% during the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after acquiring an additional 2,794 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

OGN opened at $7.55 on Friday. The stock’s 50 day simple moving average is $9.19 and its 200-day simple moving average is $9.42. The company has a current ratio of 1.75, a quick ratio of 1.13 and a debt-to-equity ratio of 9.69. The stock has a market cap of $1.96 billion, a PE ratio of 3.93, a P/E/G ratio of 1.61 and a beta of 0.59. Organon & Co. has a 1 year low of $6.18 and a 1 year high of $17.23.

Organon & Co. (NYSE:OGN) last issued its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.93 by $0.08. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same period last year, the business earned $1.38 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Thursday, November 20th will be given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 20th. Organon & Co.’s dividend payout ratio is 4.17%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. dropped their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday. Morgan Stanley dropped their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Finally, Piper Sandler lowered shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. presently has an average rating of “Hold” and a consensus target price of $12.50.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.